Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Acanthamoeba Keratitis. Read More »

According to a report published in the most recent issue of the Journal of the American Medical Association, scientists were able to determine that 6 percent of pregnancies after contracting the Zika virus infection resulted in one or more birth defects linked to Zika using data from the U.S. Zika Pregnancy Registry. Read More »

CVS Health recently held its annual Analyst Day, a meeting in which the discussions of strategies for long-term growth will be driven and shareholder value were held. Read More »

The results of a new study conducted by AARP show that pharmaceutical prices for brand name products has increased drastically. Read More »

Endo International subsidiary Par Pharmaceutical has begun the shipping process for ezetimibe 10 mg tablets, which is the generic form of ZETIA, developed by Merck. Read More »

Protagen AG has launched NavigAID SSc, its disease stratification assay that was developed to assist pharmaceutical and biotechnology companies with their efforts to develop drugs to treat Systemic Sclerosis. Read More »

Bayer's supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator has been accepted by the U.S. Food and Drug Administration. Read More »

Castle Creek Pharmaceuticals' exclusive license agreement for the rights to Arlevert in the United States has been finalized. Read More »

aTyr Pharma has released results of its exploratory clinical trials designed to evaluate the safety and potential activity of Resolaris in treating LGMD2B and FSHD. Read More »

CVS Health has launched Transform Diabetes Care, its new program set up to assist pharmacy benefits management clients in the improvement of member health outcomes, to decrease costs with aggressive trend management, and to cut medical costs by refining medication adherence. Read More »

Merck continued its release of KEYTRUDA results by reporting that its Phase 3 KEYNOTE-024 clinical trial demonstrated positive health-related quality of life. Read More »

Eiger BioPharmaceuticals has announced clinical and regulatory development advancements of exendin 9-39, which was developed to treat post-bariatric hypoglycemia. Read More »

Merck has released updated data from two clinical trials designed to assess KEYTRUDA (pembrolizumab), its anti-PD-1 therapy developed to treat patients who have relapsed or refractory classical Hodgkin lymphoma (cHL). Read More »

Merck recently released updated data from its Phase 1b KEYNOTE-028 clinical trial, which involved KEYTRUDA. Read More »

Endo International plc subsidiary Par Pharmaceutical has released mycophenolate mofetil hydrochloride as an injection in the United States after the Food and Drug Administration gave its approval of Endo’s Abbreviated New Drug Application. Read More »

Pfizer and its partner Avillion LLP have announced the results from the BFORE clinical study. Read More »

Sandoz's generic version of Latisse, bimatoprost ophthalmic solution, 0.03 percent, is now available in the United States. Read More »

Baxter International Inc. has once again earned the highest possible score of 100 percent on the 2017 Corporate Equality Index, which is produced by the Human Rights Campaign Foundation. Read More »

Endo International and BioDelivery Sciences International (BDSI) have agreed to return the BELBUCA buccal film product to BDSI. Read More »

Kite Pharma recently presented the results of its ZUMA-1 clinical trial involving axicabtagene ciloleucel (KTE-C19) at the American Society of Hematology (ASH) 58th Annual Meeting. Read More »